Can GE HealthCare Technologies (GEHC) Stock Reach $85?

Key Takeaways

• The central question is whether GEHC can climb from the low $70s back toward the $85 level, a roughly 20% move that aligns with several Street targets.
• Strong orders, a record backlog, and a push into AI-enabled imaging and theranostics are the primary bullish catalysts.
• Execution concerns, margin pressure, and China exposure remain the biggest obstacles to sustained upside.
• The 52-week range of roughly $58.75 to $89.77 means $85 sits below the prior high but well above current levels, making it a meaningful recovery zone.
• The analyst consensus points to roughly the high-$70s, so $85 would require the stock to outperform the average forecast, not just meet it.

Why Investors Are Watching the $85 Level

GE HealthCare Technologies Inc. (GEHC) is a global medical technology and diagnostics company spun off from General Electric in January 2023. After peaking near $90 within the past year, the stock pulled back and has spent recent months trading in a broad range, leaving investors asking whether it can reclaim the $85 mark. That level carries weight because it sits near the upper end of current analyst price targets and represents a clear psychological milestone on the road back to the 52-week high.

Current Market Position

The company operates across four segments — Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx) — spanning MRI, CT, PET, X-ray, ultrasound, patient monitoring, and contrast media. Its most recent quarterly results, reported in late July, showed adjusted earnings per share (EPS) of $1.13, above consensus, with revenue rising about 5.8% year over year to roughly $5.29 billion. Management also raised its full-year EPS outlook, supported by what executives described as strong orders and a record backlog.

What Could Drive the Next Leg Higher

The bull case rests on a durable order book and a portfolio shift toward higher-value digital and AI-enabled offerings. GEHC has received regulatory clearances for AI-driven imaging software and has expanded collaborations in theranostics — the pairing of diagnostic imaging with targeted radiopharmaceutical therapy — including work with leading research institutions. These initiatives target recurring, higher-margin revenue streams that could support both growth and a re-rating of the shares over time. A recovery in hospital capital spending and continued margin expansion would likely be required for the stock to sustainably approach $85.

Analyst Opinions and Price Targets

Wall Street views on GEHC are split. The consensus 12-month price target sits in the high-$70s, according to multiple data aggregators, with the highest published targets reaching the mid-$90s. Notably, several firms cluster their targets right around $85: Wells Fargo raised its objective to $85 while maintaining an Overweight rating, Argus moved to $85, and Oppenheimer and Evercore have targets near $84 to $85. On the more cautious side, firms such as Goldman Sachs, UBS, Citi, and Bank of America have maintained targets in the mid-$60s to mid-$70s, citing execution risk and valuation. In short, reaching $85 would put the stock at the optimistic end of the analyst range, not the middle.

What Could Prevent the Move

The principal risks are execution and geography. Analysts have repeatedly flagged that demand remains strong while delivery has at times lagged, with margin pressure and a supplier-related recall weighing on sentiment earlier in the year. China remains a meaningful source of uncertainty given ongoing macro and policy headwinds in that market. Because a large portion of GEHC's business depends on hospital capital equipment budgets, any slowdown in healthcare spending or renewed supply-chain disruption could delay the earnings growth needed to justify a move toward $85.

Technical Levels That Matter

From a technical standpoint, $85 functions as a supply area rather than a simple round number. The stock's 52-week high near $90 marks the clearest overhead resistance, while the low-$70s and the psychologically important $70 level represent near-term support zones. The low-$60s served as a base during periods of weakness earlier in the year. For a sustained advance toward $85, the stock would first need to hold above its longer-term moving averages and build higher lows — a process that typically requires both improving fundamentals and a supportive broader market backdrop.

AI Daily Buy/Sell Signals

Traders tracking whether GEHC can mount a sustained move may benefit from tools that monitor changing conditions in real time. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously analyze thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. These signals are designed to help traders spot emerging opportunities, monitor existing positions, and identify changing market trends more efficiently. Investors seeking a data-driven way to track potential breakouts or breakdowns may find this approach worth exploring.

Final Assessment

A move to $85 is plausible but far from guaranteed. The strongest support comes from a record backlog, rising orders, and a credible AI and theranostics pipeline, which together give the bull case a foundation beyond simple sentiment. However, $85 sits above the consensus analyst target, meaning the stock would need to outperform the Street's average expectations. Execution quality, margin trends, and conditions in China will likely determine whether the shares can sustain the kind of re-rating required to reclaim that level. Investors should monitor order-to-revenue conversion, quarterly margin performance, and any changes to the company's China outlook as the key signals of whether $85 is truly within reach.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations